Αρχική Uncategorized New Cancer Diagnoses Jump at Age 65, Suggesting People Put Off Screenings...

New Cancer Diagnoses Jump at Age 65, Suggesting People Put Off Screenings Until They Have Medicare

There are nearly 30 million uninsured Americans who are lacking coverage for a variety of reasons. It could be due to the high cost, a lack of public options in their state, or because they don’t have a plan offered through work. According to a new study, this may be playing a role in people putting off cancer screenings until they have Medicare.

Researchers from Stanford University looked at cancer diagnoses among patients in their 60s and found that there was a large increase in new lung, breast, colon, and prostate cancer cases when people hit 65. Their findings were published March 29th in the journal Cancer.

PHOTO: PIXABAY/CANDID SHOTS

Dr. Joseph Shrager, the study’s senior author and professor of cardiothoracic surgery at Stanford School of Medicine, says, “Essentially we showed there is a big jump in cancer diagnoses as people turn 65 and are thus Medicare-eligible. This suggests that many people are delaying their care for financial reasons until they get health insurance through Medicare.”

Dr. Shrager said the study came about after he and his colleagues noticed this trend in their own practices. To see if it applied more broadly, the group looked at data from more than 600,000 cancer patients in their 60s who were diagnosed with lung, breast, colon, or prostate cancer between 2004 and 2016. They found that for all four cancers, there was a larger increase in diagnoses when people turned 65 than there was for any other age transition.

Lung cancer cases increased 3-4% each year from the ages of 61 to 64. However, once people turned 65, the increase was doubled. Colon cancer stood out the most, with a roughly 1-2% increase per year until age 65, when it went up to nearly 15%. In the years following that, new diagnoses decreased for all four cancers.

PHOTO: PIXABAY/ERNESTO ESLAVA

The study also found that people aged 65-plus who were insured were more likely to have surgery to address their cancers and had a lower five-year mortality rate than younger uninsured people. The authors noted that this is consistent with other research linking insurance coverage to access to care, early diagnosis, and improved outcomes.

Dr. Shrager says, “If you don’t get the right screening or prompt diagnosis you are going to have lower cure rates. This study underlines the important difference that some sort of Medicare expansion could make.”

The authors explain that 13 to 25% of people aged 61 to 64 do not have health insurance or may have a gap in coverage before enrolling in Medicare.

The study says, “These individuals often lack insurance as a result of early retirement, pre-existing conditions hindering renewal, the high cost of private insurance and other causes.”

PHOTO: PIXABAY/AREK SOCHA

The researchers note that these issues could all play a role in putting off key health screenings and treatment until they have the peace of mind of insurance coverage. This is in line with other studies. KFF says in 2019, three in ten uninsured Americans went without needed medical care because it was too expensive.

Provide Mammograms

Support those fighting Breast Cancer at The Breast Cancer Site for free!

Whizzco Source

NEWSLETTER

Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like
57ΑκόλουθοιΑκολουθήστε

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...

ΠΑΓΚΟΣΜΙΑ ΗΜΕΡΑ ΚΑΡΚΙΝΟΥ

Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ)

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

Despite Proven Safety of HPV Vaccines, More Parents Have Concerns

October 22, 2021, by NCI Staff Credit: National Cancer Institute Despite more than 15 years of consistent evidence that HPV vaccines are safe and effective, a...

FDA Approves Atezolizumab as Adjuvant Treatment for Non-Small Cell Lung Cancer

On 15 October 2021, the US Food and Drug Administration (FDA) approved atezolizumab (Tecentriq, Genentech, Inc.) for adjuvant treatment following resection and platinum-based chemotherapy...

Breast Cancer Survivor Uses Comedy to Spread Awareness and Address Disparities

Suzette Simon lost her mother to breast cancer. In 2020, she learned that she had the disease, as well. Realizing how much harder breast...

Why Wearing Comfortable Clothes During Cancer Treatment Matters

Voices on Cancer is an award-winning Cancer.Net Blog series where advocates share their stories and the lessons they have learned about being a cancer advocate. Cindy Trice is...

Breast cancer surgery: ‘I’m proud of the tattoos inked across my chest’

Wendy had a double mastectomy in 2017 and remained flat. “When the consultant told me, I remember crying and saying that I have 2 young...

EMA Recommends Granting a Marketing Authorisation for Zanubrutinib for the Treatment of Waldenström’s Macroglobulinaemia

On 16 September 2021, the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use adopted a positive opinion, recommending the granting of...